Design Therapeutics Statistics
Total Valuation
DSGN has a market cap or net worth of $685.15 million. The enterprise value is $465.06 million.
| Market Cap | 685.15M |
| Enterprise Value | 465.06M |
Important Dates
The last earnings date was Tuesday, April 28, 2026, after market close.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DSGN has 62.46 million shares outstanding. The number of shares has increased by 3.26% in one year.
| Current Share Class | 62.46M |
| Shares Outstanding | 62.46M |
| Shares Change (YoY) | +3.26% |
| Shares Change (QoQ) | +4.60% |
| Owned by Insiders (%) | 14.26% |
| Owned by Institutions (%) | 46.15% |
| Float | 32.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.14 |
| P/TBV Ratio | 3.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.28, with a Debt / Equity ratio of 0.01.
| Current Ratio | 22.28 |
| Quick Ratio | 22.05 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.26% and return on invested capital (ROIC) is -21.72%.
| Return on Equity (ROE) | -31.26% |
| Return on Assets (ROA) | -20.93% |
| Return on Invested Capital (ROIC) | -21.72% |
| Return on Capital Employed (ROCE) | -35.58% |
| Weighted Average Cost of Capital (WACC) | 13.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 54 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +181.28% in the last 52 weeks. The beta is 1.66, so DSGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | +181.28% |
| 50-Day Moving Average | 12.38 |
| 200-Day Moving Average | 9.48 |
| Relative Strength Index (RSI) | 45.45 |
| Average Volume (20 Days) | 1,326,434 |
Short Selling Information
The latest short interest is 3.88 million, so 6.21% of the outstanding shares have been sold short.
| Short Interest | 3.88M |
| Short Previous Month | 2.90M |
| Short % of Shares Out | 6.21% |
| Short % of Float | 12.05% |
| Short Ratio (days to cover) | 3.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | -58.13M |
| Operating Income | -78.36M |
| Pretax Income | -69.71M |
| Net Income | -69.71M |
| EBITDA | -77.74M |
| EBIT | -78.36M |
| Earnings Per Share (EPS) | -$1.19 |
Balance Sheet
The company has $222.82 million in cash and $2.73 million in debt, with a net cash position of $220.09 million or $3.52 per share.
| Cash & Cash Equivalents | 222.82M |
| Total Debt | 2.73M |
| Net Cash | 220.09M |
| Net Cash Per Share | $3.52 |
| Equity (Book Value) | 218.05M |
| Book Value Per Share | 3.49 |
| Working Capital | 216.86M |
Cash Flow
In the last 12 months, operating cash flow was -$54.00 million and capital expenditures -$121,000, giving a free cash flow of -$54.12 million.
| Operating Cash Flow | -54.00M |
| Capital Expenditures | -121,000 |
| Depreciation & Amortization | 620,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -54.12M |
| FCF Per Share | -$0.87 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DSGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.26% |
| Shareholder Yield | -3.26% |
| Earnings Yield | -10.17% |
| FCF Yield | -7.90% |
Analyst Forecast
The average price target for DSGN is $21.00, which is 91.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.00 |
| Price Target Difference | 91.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |